Peer-Reviewed Publication
Bioeng Transl Med2021;6(1):e10196.January 1, 2021Journal Article
IDentif.AI: Rapidly optimizing combination therapy design against severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2) with digital drug development.
Agata Blasiak1,2,3, Jhin Jieh Lim4, Shirley Gek Kheng Seah5, Theodore Kee1,2,3, Alexandria Remus1,2,3, De Hoe Chye5, Pui San Wong5, Lissa Hooi4, Anh T L Truong1,2,3, Nguyen Le1,2,3, Conrad E Z Chan5, Rishi Desai6, Xianting Ding7, Brendon J Hanson5, Edward Kai-Hua Chow1,2,3,4,8, Dean Ho1,2,3,8
1The N.1 Institute for Health (N.1) National University of Singapore Singapore Singapore.
2The Institute for Digital Medicine (WisDM), Yong Loo Lin School of Medicine National University of Singapore Singapore Singapore.
3Department of Biomedical Engineering, NUS Engineering National University of Singapore Singapore Singapore.
4Cancer Science Institute of Singapore National University of Singapore Singapore Singapore.
5Defence Medical and Environmental Research Institute DSO National Laboratories Singapore Singapore.
6Osmosis Baltimore Maryland USA.
7Institute for Personalized Medicine, School of Biomedical Engineering Shanghai Jiao Tong University Shanghai China.
8Department of Pharmacology, Yong Loo Lin School of Medicine National University of Singapore Singapore Singapore.
Abstract
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) led to multiple drug repurposing clinical trials that have yielded largely uncertain outcomes. To overcome this challenge, we used IDentif.AI, a platform that pairs experimental validation with artificial intelligence (AI) and digital drug development to rapidly pinpoint unpredictable drug interactions and optimize infec…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans